Trial Profile
18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 24 Jan 2022
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Expanded access
- 06 Jan 2022 Status changed from recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 06 May 2019 According to a Progenics Pharmaceuticals media release, data from this trial were presented at the American Urological Association (AUA) Annual Meeting 2019.